Wiley Bros. Aintree Capital, LLC Vertex Pharmaceuticals Inc Transaction History
Wiley Bros. Aintree Capital, LLC
- $12.5 Billion
- Q2 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 25,140 shares of VRTX stock, worth $10.7 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
25,140
Previous 13,953
80.18%
Holding current value
$10.7 Million
Previous $6.76 Million
65.46%
% of portfolio
0.09%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,784Shares Held
236MCall Options Held
1.95MPut Options Held
1.14M-
Capital World Investors Los Angeles, CA28.7MShares$12.2 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$10.2 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.07 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.1MShares$6.86 Billion1.5% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.01 Billion0.2% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $109B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...